Delivery Order SPE2DB24D3013-SPE2DB24FFFSD
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of VYVANSE 30 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The award has a ceiling value of $1,677.39 and an ultimate completion date of June 27, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025. This...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,660.67 Firm Fixed Price Delivery Order contract is for the supply of 4567394215 ! VYVANSE 70 MG CAPSULE 100S. The contract has an ultimate completion date of February 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, is for the delivery of VYVANSE 30 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The contract, valued at $5,433.46, is a Firm Fixed Price Delivery Order with a completion date of June 28, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,752.81, is a delivery order for the supply of VYVANSE 30 MG CAPSULE 100S, a prescription medication. The contract has an ultimate completion date of November 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of VYVANSE 30 MG CAPSULE 100S. The contract, valued at $5,441.66, is a firm fixed price delivery order with a period of performance through November 7, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the provision of VYVANSE 70 MG CAPSULE 100S. The $1,929.46 firm fixed-price delivery order has an ultimate completion date of December 17, 2024 and was awarded on December 16, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award, valued at $3,045.64, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of 4,564,161,278 units of the pharmaceutical product VYVANSE 20 MG CAPSULE 100S. The award has a firm fixed price pricing type and an ultimate completion date of April 3, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $2,364.40 firm fixed price delivery order is for the supply of 4564743413 - VYVANSE 50 MG CAPSULE 100S, a prescription medication. The award date is May 29, 2024, with a completion date of May 30, 2024. This contract has no set-aside designation. Amerisourcebergen is a major pharmaceutical distribution company that holds a $999,999,999.00 Indefinite...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $3,047.72 for the supply of VYVANSE 40 MG CAPSULE 100S, a prescription medication. The contract has an ultimate completion date of November 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, as the prime contractor. The contract is for the delivery of VYVANSE CAPS 60MG, a pharmaceutical product, with a ceiling value of $11,226.44 and a performance period through April 15, 2024. The contract is a firm fixed price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp is the prime...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB24FFFSDDelivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, the corporate office division of Amerisourcebergen Corporation, a major pharmaceutical distribution company. The contract is for the delivery of 4564828902 VYVANSE 30 MG CAPSULE 100S, a prescription medication. The contract has a ceiling value of $1,547.06 and an ultimate completion date of June 7, 2024. This is a firm fixed-price delivery order contract, without a set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Additionally, Amerisourcebergen holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 6/6/24 |